1/ Darkness:
In late ‘40s, major research efforts were directed at repairing radiation damage to organs in response to observations in survivors of the horrific atomic bomb explosions in Japan. Leukaemia was the 1st cancer associated with atomic bomb radiation exposure.
2/ Results of a study in '49 showed protection of mice given an otherwise lethal dose by shielding of the spleen during the irradiation. This procedure caused an impressive reduction in mortality, and moreover the spleen appeared to be specific in this respect.
Reviewed in 👇
3/ Humoral?
Many researchers believed that radiation protection was due to some humoral factor present in spleen or bone marrow, a controversial supposition and not shared by others who thought the ‘rescue’ of the irradiated mice had cellular origins.
4/ No, cellular!
Until the mid-1950s several laboratories unequivocally documented, with the help of blood genetic markers, that radioprotection was due to repopulation of irradiated marrow spaces by transplanted donor cells.
The big hit:
In 1957, Donnall Thomas et al. reported @NEJM that marrow could be infused into irradiated leukemia patients and then engraft, even though, in the end, the patients were not cured of their leukemia.
6/ Something we hate and admire:
Previously, in 1956 Barnes et al. also showed in mice that an effect called "secondary disease" after marrow infusion could lead to eradication of leukemic cells. Effects now called "graft-versus-host” & “graft-versus-leukemia were born.
7/ A hard lesson:
Excitement led to more studies but many errors in extrapolation from the laboratory experiment to the patient have been made and much time was lost before it became evident that GVHD in primates is more violent than in rodents. Disappointment grew...
8/ In ’64, Mathé et al. described a leukemia case after TBI + marrow infusion from 6 relatives. The marrow of 1 relative engrafted. While the patient eventually succumbed to GVHD his leukemia remained in remission (GVL). Modern-day "adoptive immunotherapy" was coined.
9/ The ones that stayed on the ship:
Many left the field. But an unexpected observation by Storb et al. in a canine experiment was that GVHD developed in minor histocompatibility class (MHC) matched littermates, even though significantly later than in mismatched littermates.
10/ Let’s recap our 25 year sprint through the beginnings of BMT.
11/ GVHD is the enemy:
How to prevent GVHD in well-matched donor-recipient BMT?
👉studies of numerous immunosuppressive agents were conducted in ‘70s in a canine model that eventually led to identifying the antimetabolite methotrexate as the best drug for GVHD prevention.
12/ Riding on the storm:
A more immunosuppressive regimen was developed that combined antithymocyte globulin (ATG, from horse or rabbit) with cyclophosphamide.
This regimen has then become standard practice for aplastic anemia patients with HLA-identical sibling donors.
13/ Grading the ungrateful:
In 1974, the 1st grading system for acute GVHD was described and its 1st effective treatment ATG was reported ATG was not commercially available and thus produced in single laboratories by immunizing rabbits with human thymocytes.
14/ Return of the shadow:
Many patients still died from relapse but transplanting earlier in disease course reduced the relapse risk and led to a significant improvement in survival among patients with acute leukemia.
15/ Hope:
2 pivotal publications from 1979 and 1981 in @NEJM described powerful graft-versus- leukemia effects associated with acute and chronic GVHD, providing the rationale for the subsequent introduction of donor lymphocyte infusions in the 1990s.
16/ Let's recap what we've seen after great disappointment but resilience of the few to improve BMT from the 70s.
17/ To the mountain top, together:
One limitation in early BMT was access, only 35% had HLA-identical siblings
👉registries were built @AnthonyNolan@BeTheMatch@DKMS_de etc.
18/ Love:
Nothing is worthwhile when you do it alone. Gösta Gahrton (a European BMT pioneer) told me, BMT without Donnall AND Dotti Thomas wouldn’t exist as is. He remarked that if Donnall Thomas was considered the father of BMT, "then Dottie Thomas was the mother".
19/ Reflection:
I was born in 1990 just before his lecture, watched it 1st time few years back, still in awe of the resilience that led us to that point and beyond. I am grateful for this spirit of science and medicine.
Lecture👉 nobelprize.org/prizes/medicin…
As a new medical student 10 years ago, I often asked myself:
What makes a good doctor and researcher?
After all these years, I’m amazed by how this still remains true in my heart today.
Here’s what I thought🧵
LEARN THE BASICS WELL
Medicine is like a building: your foundation matters. Don’t rush to memorize rare diseases before you’ve mastered anatomy, physiology, and pathology. Know your basics inside out.
BE CURIOUS, NOT JUST STUDIOUS
Don’t just learn for exams. Ask yourself:
Why does this happen?
How can I explain it to someone else?
Curiosity turns a good student into a lifelong learner.
Here's a thread on selected clinical studies we've seen this year🧵🩸
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia @NEJM
- asciminib showed superior efficacy and a favorable safety profile in patients with newly diagnosed chronic-phase CML
- BUT comparison with second-generation TKIs was not a primary objective!
Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children @NEJM
- 3-year DFS was 96% with blinatumomab and chemotherapy and 88% with chemotherapy alone
- Cytokine release syndrome, seizures, and sepsis of grade 3 or higher were rare
Chimeric antigen receptor T cell therapy might revolutionize the management and our understanding of autoimmune diseases
An short educational thread🧵on current status and future directions
Intro:
- CAR T therapy was originally designed to fight cancer
- now showed transformative potential in treating autoimmune diseases by targeting B cells
👉key role in disease (progression)
- safety remains focus, with a milder toxicity profile emerging in autoimmune disease
B cells?
- arise in bone marrow and go to periphery
- differentiate into antibody-secreting plasma cell populations
👉short-lived plasmablasts + long-lived plasma cells
👉reside in bone marrow
- CD19, CD20, CD38, BCMA expressed at various stages
👉enable identification
The h-index is one of the most impactful and widely used metrics to assess a researcher’s productivity and citation impact.
How it started & how it's going
A thread🧵
History:
- 2005 by physicist Jorge E. Hirsch
- assess researcher’s productivity and citation impact
- argued that total citations are skewed by few highly cited papers
👉publication counts don’t account for influence of research
We will discuss later the "dilemma of quality"...
What's the h index?
- largest number h such that h articles have at least h citations each
👉if an author has 5 publications with 9, 7, 6, 2, 1 citations
👉h-index=3
👉3 publications with 3 or more citations
BUT
the author does not have 4 publications with >3 citations❗️
Elsevier is one of the largest, most hated and most influential academic publishing companies in the world.
How it started & how it's going
A thread🧵
Founding:
- 1580, family named Elzevir, led by Lodewijk Elzevir, founded original publishing house in Leiden🇳🇱
- family's printer's mark
👉tree entwined with a vine & the words Non Solus
👉Latin for "not alone"
👉symbiosis between publisher & scholar
We will see the irony later!
Early scoops:
- Elzevir was famed for its high-quality, small-format editions of scholarly works in 17th century
- famous publication of "Observationes Medicae", first illustration of chimpanzee
- notable other publications included works by Galileo Galilei and René Descartes
Today is World Chronic Myeloid Leukemia Day #WCMLD24
Time to educate, reflect and celebrate what has been achieved
A short educational thread on CML
Intro to CML:
-BCR-ABL1-positive
-classified as a myeloproliferative neoplasm
-predominantly composed of proliferating granulocytes and determined to have the Philadelphia chromosome/translocation t(9;22)(q34;q11.2)
-affects peripheral blood + bone marrow
Pathophysiology:
-fusion oncoprotein BCR-ABL1 defines CML
-90-95% have a shortened chromosome 22
👉reciprocal translocation t(9;22) (q34;q11.2)
👉Philadelphia chromosome
-oncoprotein acts as constitutively expressed defective tyrosine kinaseö